암을 일으킬 것으로 의심됨 (노출되어도 암을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재)
발암성 물질
구분 2
경고
P201, P202, P281, P308+P313, P405,P501
예방조치문구:
P202
모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.
P261
분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P280
보호장갑/보호의/보안경/안면보호구를 착용하시오.
P308+P313
노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
NFPA 704
0
4
0
Cyproterone acetate C화학적 특성, 용도, 생산
개요
Cyproterone acetate (CPA) is an androgen receptor antagonist. It binds to human androgen receptors (Ki = 14 nM) and inhibits dihydrotestosterone-induced androgen receptor activation in CV-1 cells (IC50 = 26 nM). CPA (30 mg/kg) decreases ventral prostate weight in castrated immature rats. It also suppresses accessory sexual glands and fertility in adult male rats when administered at a dose of 10 mg/kg. CPA (0.3 μM) also induces apoptosis in primary adult female rat hepatocytes. Formulations containing cyproterone acetate have been used in the treatment of androgenization in females.
화학적 성질
Crystalline Solid
용도
Cyproterone acetate (CPA) has been shown to exert gestagenic and glucocorticoid effects. Because it inhibits the negative diencephalic pituitary testicular feedback system, it lowers luteinizing hormone (LH) and testosterone production and plasma levels. cyproterone acetate is both an anti-androgen and a progestogen. CPA is used in combined birth control pills, in the treatment of androgen-dependent skin and hair conditions such as acne (Combined with estrogen), seborrhea, excessive hair growth, and scalp hair loss, high androgen levels, in transgender hormone therapy, to treat prostate cancer, to reduce sex drive in sex offenders or men with paraphilias or hypersexuality, to treat early puberty, and for other uses. It is used both at low doses and at higher doses.
Indications
Cyproterone acetate is a progestational antiandrogen
that blocks androgen receptor binding and suppresses
androgen-sensitive tissues. It is available in a
topical form in Europe for the treatment of hirsutism.